Authors:
Vestervall, F
Ungemach, FR
Aarestrup, FM
Teuber, M
Algers, B
Witte, W
Sorum, H
Naess, B
Skold, O
Helmuth, R
Semjen, G
Franklin, A
Morner, A
Greko, C
Citation: F. Vestervall et al., The effects of intervention on antimicrobial resistance - Discussion, ACT VET SC, 2000, pp. 111-117
Authors:
Zuber, B
Hinkula, J
Vodros, D
Lundholm, P
Nilsson, C
Morner, A
Levi, M
Benthin, R
Wahren, B
Citation: B. Zuber et al., Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge, VIROLOGY, 278(2), 2000, pp. 400-411
Authors:
Morner, A
Achour, A
Norin, M
Thorstensson, R
Bjorling, E
Citation: A. Morner et al., Fine characterization of a V3-region neutralizing epitope in human immunodeficiency virus type 2, VIRUS RES, 59(1), 1999, pp. 49-60
Authors:
Morner, A
Bjorndal, A
Albert, J
Kewalramani, VN
Littman, DR
Inoue, R
Thorstensson, R
Fenyo, EM
Bjorling, E
Citation: A. Morner et al., Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage, J VIROLOGY, 73(3), 1999, pp. 2343-2349
Authors:
Bjorling, E
von Garrelts, E
Morner, A
Ehnlund, M
Persson, MAA
Citation: E. Bjorling et al., Human neutralizing human immunodeficiency virus type 2-specific Fab molecules generated by phage display, J GEN VIROL, 80, 1999, pp. 1987-1993